Insights into the role of senescence in tumor dormancy: mechanisms and applications
- PMID: 36681750
- DOI: 10.1007/s10555-023-10082-6
Insights into the role of senescence in tumor dormancy: mechanisms and applications
Abstract
One of the most formidable challenges in oncology and tumor biology research is to provide an accurate understanding of tumor dormancy mechanisms. Dormancy refers to the ability of tumor cells to go undetected in the body for a prolonged period, followed by "spontaneous" escape. Various models of dormancy have been postulated, including angiogenic, immune-mediated, and cellular dormancy. While the former two propose mechanisms by which tumor growth may remain static at a population level, cellular dormancy refers to molecular processes that restrict proliferation at the cell level. Senescence is a form of growth arrest, during which cells undergo distinct phenotypic, epigenetic, and metabolic changes. Senescence is also associated with the development of a robust secretome, comprised of various chemokines and cytokines that interact with the surrounding microenvironment, including other tumor cells, stromal cells, endothelial cells, and immune cells. Both tumor and non-tumor cells can undergo senescence following various stressors, many of which are present during tumorigenesis and therapy. As such, senescent cells are present within forming tumors and in residual tumors post-treatment and therefore play a major role in tumor biology. However, the contributions of senescence to dormancy are largely understudied. Here, we provide an overview of multiple processes that have been well established as being involved in tumor dormancy, and we speculate on how senescence may contribute to these mechanisms.
Keywords: Angiogenic; Autophagy; Cancer; Dormancy; Immunogenic; Polyploidy; Recurrence; Senescence.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Could senescence phenotypes strike the balance to promote tumor dormancy?Cancer Metastasis Rev. 2023 Mar;42(1):143-160. doi: 10.1007/s10555-023-10089-z. Epub 2023 Feb 3. Cancer Metastasis Rev. 2023. PMID: 36735097 Free PMC article. Review.
-
Can 3D bioprinting solve the mystery of senescence in cancer therapy?Ageing Res Rev. 2022 Nov;81:101732. doi: 10.1016/j.arr.2022.101732. Epub 2022 Sep 12. Ageing Res Rev. 2022. PMID: 36100069 Review.
-
Non-Cell-Autonomous Regulation of Cellular Senescence in Cancer.Trends Cell Biol. 2016 Mar;26(3):215-226. doi: 10.1016/j.tcb.2015.10.005. Epub 2015 Nov 9. Trends Cell Biol. 2016. PMID: 26564316 Review.
-
Cellular senescence in glioma.J Neurooncol. 2023 Aug;164(1):11-29. doi: 10.1007/s11060-023-04387-3. Epub 2023 Jul 17. J Neurooncol. 2023. PMID: 37458855 Review.
-
Beyond Tumor Suppression: Senescence in Cancer Stemness and Tumor Dormancy.Cells. 2020 Feb 3;9(2):346. doi: 10.3390/cells9020346. Cells. 2020. PMID: 32028565 Free PMC article. Review.
Cited by
-
Targeting therapy-induced senescence as a novel strategy to combat chemotherapy-induced peripheral neuropathy.Support Care Cancer. 2024 Jan 5;32(1):85. doi: 10.1007/s00520-023-08287-0. Support Care Cancer. 2024. PMID: 38177894 Review.
-
Balancing senescence and apoptosis: therapeutic insights into aging and cancer.Mol Cell Biochem. 2025 Jul 19. doi: 10.1007/s11010-025-05355-3. Online ahead of print. Mol Cell Biochem. 2025. PMID: 40682710
-
A three-marker signature identifies senescence in human breast cancer exposed to neoadjuvant chemotherapy.Cancer Chemother Pharmacol. 2023 Apr;91(4):345-360. doi: 10.1007/s00280-023-04523-w. Epub 2023 Mar 24. Cancer Chemother Pharmacol. 2023. PMID: 36964435
-
Targeting autophagy promotes the antitumor effect of radiotherapy on cervical cancer cells.Cancer Biol Ther. 2024 Dec 31;25(1):2431136. doi: 10.1080/15384047.2024.2431136. Epub 2024 Dec 5. Cancer Biol Ther. 2024. PMID: 39635971 Free PMC article.
-
Exosomes Derived from Induced and Wharton's Jelly-Derived Mesenchymal Stem Cells Promote Senescence-like Features and Migration in Cancer Cells.Int J Mol Sci. 2025 Jun 26;26(13):6178. doi: 10.3390/ijms26136178. Int J Mol Sci. 2025. PMID: 40649957 Free PMC article.
References
-
- Labonte, M. J., Bohanes, P., Zhang, W., Benhanim, L., Ning, Y., Wakatsuki, T., & David, P. (2012). Cancer dormancy: A model of early dissemination and late cancer recurrence. Clinical Cancer Research, 18(3), 645–654. https://doi.org/10.1158/1078-0432.CCR-11-2186 - DOI - PubMed
-
- Morgan, T. M., Lange, P. H., Porter, M. P., Lin, D. W., Ellis, W. J., Gallaher, I. S., & Vessella, R. L. (2009). Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clinical Cancer Research, 15(2), 677–683. https://doi.org/10.1158/1078-0432.CCR-08-1754 - DOI - PubMed - PMC
-
- Janni, W., Vogl, F. D., Wiedswang, G., Synnestvedt, M., Fehm, T., Jückstock, J., & Naume, B. (2011). Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse–A European pooled analysis. Clinical Cancer Research, 17(9), 2967–2976. https://doi.org/10.1158/1078-0432.CCR-10-2515 - DOI - PubMed
-
- Sosa, M. S., Bragado, P., & Aguirre-Ghiso, J. A. (2014). Mechanisms of disseminated cancer cell dormancy: An awakening field. Nature Reviews Cancer, 14(9), 611–622. https://doi.org/10.1038/nrc3793.Mechanisms - DOI - PubMed - PMC
-
- Naumov, G. N., Folkman, J., & Straume, O. (2009). Tumor dormancy due to failure of angiogenesis: Role of the microenvironment. Clinical and Experimental Metastasis, 26(1), 51–60. https://doi.org/10.1007/S10585-008-9176-0 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials